Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC)

被引：0
|
作者：
Aqel, Osama
Shen, Yunrong
Alfayoumi, Ibrahim
Abraham, Ivo
机构：
[1] Univ Arizona, Ctr Hlth Outcomes & Pharmacoecon Res, Tucson, AZ USA
[2] Univ Arizona Pharm, Dept Pharm Practice & Sci, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4081
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
    Choe, Jung Wan
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2023, 82 (02): : 105 - 106
  • [2] Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
    Rimini, Margherita
    Loi, Eleonora
    Rizzato, Mario Domenico
    Pressiani, Tiziana
    Vivaldi, Caterina
    Gusmaroli, Eleonora
    Antonuzzo, Lorenzo
    Martinelli, Erika
    Garajova, Ingrid
    Giordano, Guido
    Lucchetti, Jessica
    Schirripa, Marta
    Cornara, Noemi
    Rossari, Federico
    Vitiello, Francesco
    Amadeo, Elisabeth
    Persano, Mara
    Piva, Vittoria Matilde
    Balsano, Rita
    Salani, Francesca
    Pircher, Chiara
    Cascinu, Stefano
    Niger, Monica
    Fornaro, Lorenzo
    Rimassa, Lorenza
    Lonardi, Sara
    Scartozzi, Mario
    Zavattari, Patrizia
    Casadei-Gardini, Andrea
    TARGETED ONCOLOGY, 2024, 19 (02) : 223 - 235
  • [3] Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
    Margherita Rimini
    Eleonora Loi
    Mario Domenico Rizzato
    Tiziana Pressiani
    Caterina Vivaldi
    Eleonora Gusmaroli
    Lorenzo Antonuzzo
    Erika Martinelli
    Ingrid Garajova
    Guido Giordano
    Jessica Lucchetti
    Marta Schirripa
    Noemi Cornara
    Federico Rossari
    Francesco Vitiello
    Elisabeth Amadeo
    Mara Persano
    Vittoria Matilde Piva
    Rita Balsano
    Francesca Salani
    Chiara Pircher
    Stefano Cascinu
    Monica Niger
    Lorenzo Fornaro
    Lorenza Rimassa
    Sara Lonardi
    Mario Scartozzi
    Patrizia Zavattari
    Andrea Casadei-Gardini
    Targeted Oncology, 2024, 19 : 223 - 235
  • [4] Gemcitabine Plus Cisplatin Versus Gemcitabine Chemotherapy for Advanced Biliary Tract Cancer
    Park, Jin Myung
    Ryu, Ji Kon
    Paik, Woo Hyun
    Song, Byeong Jun
    Park, Joo Kyung
    Kim, Yong-Tae
    Yoon, Yong Bum
    GASTROENTEROLOGY, 2013, 144 (05) : S529 - S529
  • [5] Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
    Shionoya, Kento
    Sofuni, Atsushi
    Mukai, Shuntaro
    Yamauchi, Yoshiya
    Tsuchiya, Takayoshi
    Tanaka, Reina
    Tonozuka, Ryosuke
    Yamamoto, Kenjiro
    Nagai, Kazumasa
    Matsunami, Yukitoshi
    Kojima, Hiroyuki
    Minami, Hirohito
    Hirakawa, Noriyuki
    Zhan, Qiang
    Itoi, Takao
    CANCERS, 2025, 17 (02)
  • [6] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
    Rimini, Margherita
    Fornaro, Lorenzo
    Rizzato, Mario Domenico
    Antonuzzo, Lorenzo
    Rossari, Federico
    Satake, Tomoyuki
    Vandeputte, Hanne
    Vivaldi, Caterina
    Pressiani, Tiziana
    Lucchetti, Jessica
    Kim, Jin Won
    Abidoye, Oluseyi
    Rapposelli, Ilario Giovanni
    Tamberi, Stefano
    Finkelmeier, Fabian
    Giordano, Guido
    Nichetti, Federico
    Chon, Hong Jae
    Braconi, Chiara
    Pirrone, Chiara
    Castet, Florian
    Tamburini, Emiliano
    Yoo, Changhoon
    Parisi, Alessandro
    Diana, Anna
    Scartozzi, Mario
    Prager, Gerald W.
    Avallone, Antonio
    Schirripa, Marta
    Kim, Il Hwan
    Perkhofer, Lukas
    Oneda, Ester
    Verrico, Monica
    Adeva, Jorge
    Chan, Stephen L.
    Spinelli, Gian Paolo
    Personeni, Nicola
    Garajova, Ingrid
    Rodriquenz, Maria Grazia
    Leo, Silvana
    Salani, Francesca
    De Rosa, Antonio
    Lavacchi, Daniele
    Foti, Silvia
    Ikeda, Masafumi
    Dekervel, Jeroen
    Niger, Monica
    Balsano, Rita
    Tonini, Giuseppe
    Kang, Minsu
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [7] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
    Gardini, A. Casadei
    Fornaro, L.
    Lonardi, S.
    Satake, T.
    Lucchetti, J.
    Antonuzzo, L.
    Kim, J. W.
    Bekaii-Saab, T.
    Rapposelli, I. G.
    Boccaccino, A.
    Finkelmeier, F.
    Giordano, G.
    Niger, M.
    Chon, H. J.
    Braconi, C.
    Lopez-Valbuena, D.
    Farinea, G.
    Rimassa, L.
    Rimini, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S124 - S124
  • [8] Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).
    Vogel, Arndt
    Chen, Li-Tzong
    He, Aiwu Ruth
    Kim, Jin Won
    Chen, Ming-Huang
    McNamara, Mairead Geraldine
    Shimizu, Satoshi
    Gillmore, Roopinder
    Rey, Felipe
    Kim, Hyosung
    Xiong, Julia
    Makowsky, Mallory
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
    Park, Joon Oh
    Oh, Do-Youn
    Hsu, Chiun
    Chen, Jen-Shi
    Chen, Li-Tzong
    Orlando, Mauro
    Kim, Jong Seok
    Lim, Ho Yeong
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 343 - 361
  • [10] Cisplatin plus Gemcitabine for Biliary Tract Cancer
    Cariati, Andrea
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02): : 192 - 192
12345